Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV001108669 | SCV001265935 | uncertain significance | Imerslund-Grasbeck syndrome type 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Fulgent Genetics, |
RCV002497519 | SCV002783345 | uncertain significance | Imerslund-Grasbeck syndrome type 1; Proteinuria, chronic benign | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004978019 | SCV005567732 | uncertain significance | Inborn genetic diseases | 2024-11-23 | criteria provided, single submitter | clinical testing | The c.2318C>G (p.T773S) alteration is located in exon 18 (coding exon 18) of the CUBN gene. This alteration results from a C to G substitution at nucleotide position 2318, causing the threonine (T) at amino acid position 773 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |